PDF(Pubmed)
Abstract：
Background: Qingfei Paidu decoction (QFPDD) has been widely used in treating coronavirus disease 2019 (COVID-19) in China. However, studies on the treatment effect of COVID-19 patients and other respiratory diseases have not been well demonstrated. Our study aims to determine the treatment effect of QFPDD in combination with conventional treatment on COVID-19 patients and other respiratory diseases. Methods: This retrospective study recruited COVID-19 patients who were treated with QFPDD for at least two courses (6 days) from seven hospitals in five provinces from January 21 to March 18 2020. Demographic, epidemiological, clinical, laboratory, computed tomography characteristics, treatment, and outcome data were collected and analyzed. The improvements in clinical symptoms before and after QFPDD treatment were compared. Results: Eight COVID-19 patients were included in this study. Of them, six were males (75.0%). The median age of the patients was 66 (60-82) years. Four patients were classified as mild and moderate cases (50.0%); there were two severe cases (25.0%) and critical cases (25.0%). The most common symptom was cough (7 [87.5%]), followed by fever (6 [75.0%]), fatigue (4 [50.0%]), asthma (4 [50.0%]), and anorexia (3 [37.5%]). Abnormal findings included decrease in neutrophils (3 [37.5%]), lymphocytes (2 [25.0%]), alkaline phosphatase (3 [37.5%]), lactic dehydrogenase (4 [50.0%]), erythrocyte sedimentation rate (2 [25.0%]), and C-reactive protein (5 [83.3%]) at admission. After one course (3 days) of QFPDD, nasal obstruction and sore throat completely disappeared, and fever (5 [83.3%]), fatigue (2 [50.0%]), and cough (2 [28.6%]) were improved. After two courses (6 days), the fever disappeared completely in all patients, and the other symptoms showed a tendency to improve. In non-severe patients, 87.5% baseline symptoms completely disappeared. In severe patients, 61.1% of the baseline symptoms completely disappeared after patients were administered QFPDD for two courses. Of the abnormal indicators, 55.6% returned to normal levels. The median duration to complete fever recovery was 1.0 day. The median durations of viral shedding and hospitalization were 10.5 and 21.5 days, respectively. None of the patients worsened and died, and no serious adverse events occurred related to QFPDD during hospitalization. Conclusion: QFPDD combined with conventional treatment improved clinical symptoms in COVID-19 patients with other respiratory diseases, and no serious adverse reactions associated with QFPDD were observed. Larger sample studies confirm our findings in the future.
摘要：
背景：清肺排毒汤（QFPDD）已在中国广泛用于治疗冠状病毒病2019（COVID-19）。然而,关于COVID-19患者和其他呼吸系统疾病的治疗效果的研究尚未得到很好的证明。我们的研究旨在确定QFPDD联合常规治疗对COVID-19患者和其他呼吸系统疾病的治疗效果。方法：这项回顾性研究招募了2020年1月21日至3月18日在5个省的7家医院接受QFPDD治疗至少2个疗程（6天）的COVID-19患者。人口统计,流行病学,临床,实验室,计算机断层扫描特征，治疗,收集和分析结果数据。比较QFPDD治疗前后临床症状的改善情况。结果：本研究纳入了8例COVID-19患者。其中,6人为男性(75.0%)。患者的中位年龄为66(60-82)岁。4例患者分为轻度和中度病例（50.0％）；有2例严重病例（25.0％）和重症病例（25.0％）。最常见的症状是咳嗽（7[87.5%]），其次是发烧(6[75.0%])，疲劳(4[50.0%])，哮喘（4[50.0%]），和厌食症（3[37.5%]）。异常发现包括中性粒细胞减少（3[37.5%]），淋巴细胞（2[25.0%]），碱性磷酸酶(3[37.5%]),乳酸脱氢酶（4[50.0%]），红细胞沉降率（2[25.0%]），入院时C反应蛋白（5[83.3%]）。经过一个疗程（3天）的QFPDD，鼻塞和喉咙痛完全消失，和发烧（5[83.3%]），疲劳(2[50.0%])，咳嗽(2[28.6%])得到改善。经过两个课程（6天），所有患者的发烧完全消失了，其他症状有改善的趋势.在非重症患者中，87.5%的基线症状完全消失。在重症患者中，61.1％的基线症状在患者给予QFPDD两个疗程后完全消失。在异常指标中，55.6%恢复到正常水平。完全发热恢复的中位持续时间为1.0天。病毒脱落和住院的中位持续时间为10.5天和21.5天，分别。没有一个病人恶化和死亡，住院期间未发生与QFPDD相关的严重不良事件.结论:QFPDD联合常规治疗可改善COVID-19合并其他呼吸系统疾病患者的临床症状,未观察到与QFPDD相关的严重不良反应。更大的样本研究证实了我们未来的发现。
